Indian-origin pharma magnate Tonmoy Sharma was arrested in Los Angeles for masterminding a massive $149 million healthcare fraud. Authorities say his intricate scheme has sent shockwaves through the US healthcare system, reports the Times of India
Browsing: pharmaceutical industry
On a secluded island in China, cancer patients are embarking on a journey of hope as they take part in groundbreaking trials for cutting-edge experimental drugs. These pioneering therapies are not just treatments; they represent a bold leap forward in the fight against cancer, with the potential to revolutionize patient outcomes and bring new light to those facing limited options.
In a daring initiative to tackle soaring healthcare expenses, the US government is setting its sights on pharmaceutical companies, demanding significant reductions in drug prices. At the same time, India’s thriving generics market stands resilient and largely unaffected, prompting intriguing discussions about the shifting landscape of global pricing dynamics.
Exciting news from Lipocine Inc.! The company has just unveiled a groundbreaking license and supply agreement for its innovative testosterone replacement therapy, TLANDO®, in Brazil. This strategic partnership is set to broaden access to this vital treatment across the Brazilian market, significantly boosting Lipocine’s presence on the global stage.
An Indian drugmaker, once under the microscope of ProPublica, has announced a recall of two dozen medications that were sent to patients across the U.S. This alarming development has sparked fresh concerns about the safety and quality of drugs, especially in light of previous investigations that uncovered troubling issues within the company.
Chiesi has invested €430 million in a new facility in Italy, aiming to bolster its production capabilities. Meanwhile, Bharat Biotech has inaugurated its first cell and gene therapy (CGT) site in India, marking a significant advancement in the region’s biopharmaceutical landscape.
SNBL and Tasso, Inc. have announced a strategic joint venture in Japan aimed at advancing innovative healthcare solutions. This collaboration is set to enhance patient accessibility to advanced diagnostic tools in the region, strengthening both companies’ market presence.
Eli Lilly is set to introduce its weight-loss drug in emerging markets this year, aiming to address rising obesity rates. The launch follows successful outcomes in developed regions, positioning Lilly to expand its global footprint in the competitive weight management sector.
A recent investigation by BBC reveals that an Indian pharmaceutical company is significantly contributing to West Africa’s escalating opioid crisis. The report highlights alarming practices, including the production and distribution of potent opioids, raising concerns about public health and regulatory oversight in the region.